Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2022-05-17 Regulatory Filings
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
ERYTECH tiendra une présentation à la conférence H.C. Wainwright Global Investment
Regulatory Filings Classification · 1% confidence The document is a press release dated May 17, 2022, announcing that the CEO of ERYTECH Pharma will be presenting at the 'H.C. Wainwright Global Investment Conference' between May 23 and May 26, 2022. It details the time of the presentation and the availability for one-on-one investor meetings. This type of announcement, which publicizes a company's participation in an external investor event (conference presentation, roadshow, etc.), is best classified as an Investor Presentation (IP) if it were the presentation itself, or an announcement about such an event. Since the document is an announcement *about* a presentation at an investment conference, and it is short (under 5,000 characters) and serves to inform investors about upcoming engagement opportunities, it aligns closely with the purpose of an Investor Presentation (IP) or a general announcement. Given the options, 'Investor Presentation (IP)' is the most fitting category for materials related to corporate presentations aimed at investors, even if this specific document is the announcement of the presentation rather than the slides themselves. However, if we strictly follow the 'MENU VS MEAL' rule, an announcement about a future event might lean towards a general Regulatory Filing (RNS) or a Report Publication Announcement (RPA) if it were announcing the release of a formal report. Since this is about a conference presentation, and the content is promotional/informational for investors, IP is the strongest fit for the *topic*, but RPA/RNS might fit the *format* (short announcement). Given the context of financial reporting databases, announcements about executive participation in major investor conferences are often grouped with Investor Presentations (IP) or sometimes Earnings Releases (ER) if tied to results. Since it is purely about a conference presentation, and not a formal report release, I will classify it as an Investor Presentation (IP) as it directly relates to investor engagement materials, or potentially RPA if interpreted as an announcement of an upcoming event/material. Given the focus on the presentation itself, IP is chosen as the primary intent is investor communication regarding corporate strategy/pipeline updates at the conference.
2022-05-17 French
ERYTECH to Present at the H.C. Wainwright Global Investment Conference
Regulatory Filings Classification · 1% confidence The document is a press release announcing that the CEO of ERYTECH Pharma will be presenting at the H.C. Wainwright Global Investment Conference. This type of announcement, which details participation in an external investor event (conference presentation and one-to-one meetings), is typically classified as an Investor Presentation (IP) or a general announcement related to investor relations activities. Since the document itself is not the presentation slides or the transcript of the presentation, but rather the announcement *about* the presentation, it fits best under Investor Presentation (IP) as it is directly related to investor outreach and scheduled presentations, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the specific nature of announcing participation in a major investment conference, 'IP' (Investor Presentation) is the most fitting category among the provided options, as it relates to the material being presented to investors, even if this document is just the notice. However, looking closely at the definitions, 'IP' is for the presentation itself. This document is an announcement *of* participation. Since there is no specific category for 'Investor Conference Participation Announcement', and it is not a financial report (ER, IR, 10-K) or a management change (MANG), the most appropriate general category for corporate news that doesn't fit elsewhere is 'RNS' (Regulatory Filings/General Regulatory Announcements). Given the context of investor outreach, 'IP' is often used broadly for related news, but 'RNS' is the safer fallback for announcements. Let's re-evaluate: The content is purely about an upcoming presentation at an investment conference. This is a standard form of investor communication. While 'IP' is for the presentation, this announcement serves the same purpose of informing the market about investor engagement. In many databases, such announcements are grouped with Investor Presentations or Earnings Releases. Since it is not an earnings release, and it is a specific communication about investor engagement, I will lean towards 'IP' as the intended category for investor-facing event news, even if it's the announcement rather than the material itself, as it is more specific than RNS.
2022-05-17 English
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2022
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 avril 2022" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of April 30, 2022). It explicitly references Article 223-16 of the General Regulation of the Autorité des Marchés Financiers (AMF), which mandates monthly disclosure of total voting rights and share capital. This type of periodic disclosure regarding share capital structure and voting rights is a specific regulatory requirement. While it is a regulatory filing, the specific nature points towards a disclosure related to capital structure changes or share count updates, which is often categorized under Share Issue/Capital Change (SHA) or sometimes as a general Regulatory Filing (RNS). However, given the focus on the total number of shares and voting rights, it most closely aligns with disclosures related to the capital structure. Since there isn't a specific code for 'Monthly Voting Rights Disclosure', and it is a mandatory regulatory update concerning the share base, SHA (Share Issue/Capital Change) is the most relevant category among the provided options, although RNS is a possibility if SHA is interpreted strictly as new issuance/buybacks rather than routine reporting. Given the context of mandatory periodic reporting on the capital base, SHA is a strong fit, but RNS (Regulatory Filings) is the safest fallback for mandatory, non-standard reports. Let's re-evaluate the options. This is a routine, mandatory disclosure about the capital base, not a major event like a dividend or a merger. It is a specific regulatory disclosure. Since 'SHA' covers capital changes, and this reports the current state of capital, it fits. If we consider the strict definitions, this is a routine regulatory update. Given the options, and the fact that it is a specific, recurring regulatory disclosure about the share base, I will classify it as RNS (Regulatory Filings) as it is a general regulatory announcement that doesn't fit the more specific event-driven codes like DIV, SHA (new issuance), or DIRS (insider trading). It is a standard regulatory report required monthly.
2022-05-13 French
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022
Regulatory Filings Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2022." It explicitly references Article 223-16 of the French Autorité des Marchés Financiers (AMF) regulation and provides a table detailing the evolution of the total number of shares and voting rights over several months, ending on April 30, 2022. This type of regular disclosure concerning the total share capital and voting rights structure is a specific regulatory requirement, often falling under general regulatory announcements or specific capital structure updates. Since there is no specific code for 'Total Voting Rights Disclosure', and it is a mandatory regulatory filing providing key structural data, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not an earnings release (ER), interim report (IR), or a specific director dealing (DIRS). It is a mandatory periodic disclosure.
2022-05-13 English
ERYTECH fait le point sur ses activités et publie ses résultats financiers du premier trimestre 2022
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial update from ERYTECH Pharma for Q1 2022. It contains detailed financial tables (balance sheet/income statement data), management commentary on business activities, and forward-looking statements. It is not a mere announcement of a report (RPA) because it provides the actual financial data and analysis within the text. It fits the definition of an Interim/Quarterly Report (IR) as it covers a period shorter than a full fiscal year and includes substantive financial statements. Q1 2022
2022-05-12 French
ERYTECH Provides Business and Financial Update for the First Quarter of 2022
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly business and financial update from ERYTECH Pharma for the first quarter of 2022. It contains detailed financial tables (Q1 2022 vs Q1 2021), business highlights, and forward-looking statements. While it mentions an upcoming conference call, the document itself provides the substantive financial data and analysis for the interim period, qualifying it as an Interim/Quarterly Report (IR) rather than just an announcement or a transcript. Q1 2022
2022-05-12 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.